Appendix Table C33Nasal symptom outcomes: change from baseline–intranasal corticosteroid versus nasal antihistamine

Author, YearDrug, Dose/DayN/nTime, weeksCongestionpRhinorrheapSneezingpItchingpTNSSp
Carr, 2012 (Trial 1)Fluticasone propionate 200mcg207/2072-1.2 (1.3)NR-1.3 (1.4)NR-1.5 (1.4)NR-1.3 (1.3)NR-5.0 (4.7)aNR
Azelastine 548mcg208/208-0.9 (1.3)-1.1 (1.4)-1.3 (1.3)-0.9 (1.3)-4.1 (4.6)a
Carr, 2012 (Trial 2)Fluticasone propionate 200mcg189/1892-1.1 (1.5)NR-1.3 (1.5)NR-1.4 (1.5)NR-1.2 (1.4)NR-5.0 (5.2)aNR
Azelastine 548mcg194/194-1.0 (1.3)-1.0 (1.3)-1.3 (1.5)-1.1 (1.3)-4.4 (4.6)a
Carr, 2012 (Trial 3)Fluticasone propionate 200mcg450/4502-1.1 (1.2)NR-1.3 (1.4)NR-1.5 (1.5)NR-1.2 (1.3)NR-5.1 (4.7)aNR
Azelastine 548mcg445/445-1.0 (1.2)-1.2 (1.4)-1.4 (1.5)-1.1 (1.4)-4.5 (4.8)a
Ghimire, 2007Beclomethasone dipropionate 400mcg25bc2-1.8dNR-2.2dNR-2.3dNR
Azelastine 1120mcg25bc-1d-2.2d-2.2d
Hampel, 2010Fluticasone propionate 200mcg153/1512-0.86NR-1.15NR-0.98NR-0.91NR-3.84 (4.76)aNR
Azelastine 548mcg152/152-0.75-0.87-0.86-0.82-3.25 (4.16)a
Kaliner, 2009Fluticasone propionate 200mcg65/652-29.3eNS-40.3eNS-41eNS-42.8eNS3.1d0.68
Olopatadine 4 puffs/nostril65/65-22.4e-38.7e-53.9e-29.4e3.2d
Newson-Smith, 1997Beclomethasone dipropionate 400mcg83bc2-0.8NS-1NS-1NS-0.9NS
Azelastine 1120mcg83bc-0.3-0.6-0.6-0.5
Pelucchi, 1995Beclomethasone dipropionate 200mcg15/132NS
Azelastine 560mcg15/10
Ratner, 2008Fluticasone propionate 200mcg50/492-1.1 (1.2)NR-1.3 (1.2)NR-1.5 (1.5)NR-1.3 (1.5)NR-5.2 (4.6)aNR
Azelastine 4 puffs/nostril49/49-1.1 (1.5)-1.1 (1.4)-1.5 (1.0)-1.1 (1.4)-4.8 (4.3)a
Ghimire, 2007Beclomethasone dipropionate 400mcg25bc3-0.3fNR-0.3fNR-0.2fNR
Azelastine 1120mcg25bc-0.8f-0.3f-0.2f
Pelucchi, 1995Beclomethasone dipropionate 200mcg15/133-3.4gNS
Azelastine 560mcg15/10-4.5g
Ghimire, 2007Beclomethasone dipropionate 400mcg25bc4-0.1hNR-0.1hNR-0.1hNS
Azelastine 1120mcg25bc-0.6h-0.1h-0.1h
Pelucchi, 1995Beclomethasone dipropionate 200mcg15/134-2.7iNS
Azelastine 560mcg15/10-3.7i
Pelucchi, 1995Beclomethasone dipropionate 200mcg15/135-2.1jNS
Azelastine 560mcg15/10-3.5j

N/n = Number of patients randomized/number of patients analyzed; NR = not reported; NS = non-significant; TNSS = total nasal symptom score.

Except as noted, entries for each symptom represent the mean change from baseline symptom score using a 0 (no symptom) to 3 (severe symptom) rating scale. TNSS ranges from 0 to 12.

Values in parentheses are standard deviations.

a

TNSS is a sum of AM and PM scores ranging from 0 to 24.

b

Overall demographic info provided only.

c

Only patients randomized are reported.

d

Values calculated by report author.

e

Percent change from baseline.

f

Endpoint for third week.

g

Average for third week.

h

Endpoint for fourth week.

i

Average for fourth week.

j

Average for fifth week.

From: Appendix C, Evidence Tables

Cover of Treatments for Seasonal Allergic Rhinitis
Treatments for Seasonal Allergic Rhinitis [Internet].
Comparative Effectiveness Reviews, No. 120.
Glacy J, Putnam K, Godfrey S, et al.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.